Entrada Therapeutics, Inc.
TRDADrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 5, 2026
26dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
How TRDA's past catalysts played out
ENTR-601-44
Duchenne Muscular Dystrophy (DMD)
ENTR-601-45
Duchenne Muscular Dystrophy (DMD)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ENTR-601-44 | Phase 2 | Duchenne Muscular Dystrophy (DMD) | - | - |
ENTR-601-45 | Phase 2 | Duchenne Muscular Dystrophy (DMD) | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Entrada Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Entrada Therapeutics, Inc.'s (TRDA) pipeline across Phase 2. Its lead program is ENTR-601-44 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Entrada Therapeutics, Inc.'s next FDA catalyst?→
Entrada Therapeutics, Inc.'s (TRDA) next tracked catalyst is a Earnings expected August 5, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track TRDA biotech catalysts?→
Add TRDA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Entrada Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.